Events & Presentations Upcoming Events No upcoming events at this time Past Events Leerink Conference Mar 11, 2026 at 8:00 AM EDT Click here for webcast Investor Presentations ARS Pharma Corporate Presentation ARS Pharma Corporate Presentation 4 MB Aug 9, 2024 neffy® FDA Approval Call Supporting Materials neffy FDA Approval Call (August 2024) 5.9 MB Mar 7, 2024 at 1:00 PM EST Neffy® Investor Day To view the webcast, click here Supporting Materials neffy investor day presentation (Mar 2024) 10.1 MB Scientific Presentations ACAAI Poster 2024 BP Increase Blood Pressure and Pulse Rate Increases Without Concomitant Epinephrine Increases During Acute Allergic Reactions 683.1 KB ACCAI Poster 2024 EPI 10 JP03 neffy, Epinephrine Nasal Spray, Development, from Pharmacokinetics and Pharmacodynamics to Real-World Data in Pediatric Food Allergy Patients 905.4 KB ACAAI Poster 2024 HF Packaging Successful Administration of neffy, Epinephrine Nasal Spray, When Provided with a Two-Dose Carrying Case– A Human Factor Study 1.2 MB AAAAI 2024 Phase 2 Urticaria Results ARS-2 (neffy), Low-Dose Intranasal Epinephrine, Improves Urticaria Scores in Patients with Frequent Urticaria Flares: Phase 2 Study Results 567.4 KB AAAAI 2024 Quality of Life Effect of Needle-Free Epinephrine on Food Allergy Patient and Caregiver Quality of Life 1 MB AAAAI 2024 Epinephrine Utilization A Survey of Allergists, Pediatricians, and Primary Care Physicians About the Utilization of Epinephrine 1.1 MB AAAAI 2024 Poster CMC Comparative Stability of Three Epinephrine Products Under Extreme Temperature Conditions 514.3 KB AAAAI 2024 Poster EPI 10 Pediatric Doses of neffy (epinephrine nasal spray) Demonstrate Pharmacokinetic Profiles Equivalent to Epinephrine Injection Products 649 KB AAAAI 2024 Poster EPI JP03 neffy, Epinephrine Nasal Spray, Demonstrates a Positive Efficacy and Safety Profile for the Treatment of Allergic Reactions in Pediatric Patients at Risk of Anaphylaxis: Phase 3 Study Results 670.9 KB ACAAI 2023 Poster 7 Acute Allergic Rhinitis Increases Endogenous Epinephrine Resulting in Increased Heart Rate 678.5 KB Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Next page next › Last page last »
Investor Presentations ARS Pharma Corporate Presentation ARS Pharma Corporate Presentation 4 MB Aug 9, 2024 neffy® FDA Approval Call Supporting Materials neffy FDA Approval Call (August 2024) 5.9 MB Mar 7, 2024 at 1:00 PM EST Neffy® Investor Day To view the webcast, click here Supporting Materials neffy investor day presentation (Mar 2024) 10.1 MB Scientific Presentations ACAAI Poster 2024 BP Increase Blood Pressure and Pulse Rate Increases Without Concomitant Epinephrine Increases During Acute Allergic Reactions 683.1 KB ACCAI Poster 2024 EPI 10 JP03 neffy, Epinephrine Nasal Spray, Development, from Pharmacokinetics and Pharmacodynamics to Real-World Data in Pediatric Food Allergy Patients 905.4 KB ACAAI Poster 2024 HF Packaging Successful Administration of neffy, Epinephrine Nasal Spray, When Provided with a Two-Dose Carrying Case– A Human Factor Study 1.2 MB AAAAI 2024 Phase 2 Urticaria Results ARS-2 (neffy), Low-Dose Intranasal Epinephrine, Improves Urticaria Scores in Patients with Frequent Urticaria Flares: Phase 2 Study Results 567.4 KB AAAAI 2024 Quality of Life Effect of Needle-Free Epinephrine on Food Allergy Patient and Caregiver Quality of Life 1 MB AAAAI 2024 Epinephrine Utilization A Survey of Allergists, Pediatricians, and Primary Care Physicians About the Utilization of Epinephrine 1.1 MB AAAAI 2024 Poster CMC Comparative Stability of Three Epinephrine Products Under Extreme Temperature Conditions 514.3 KB AAAAI 2024 Poster EPI 10 Pediatric Doses of neffy (epinephrine nasal spray) Demonstrate Pharmacokinetic Profiles Equivalent to Epinephrine Injection Products 649 KB AAAAI 2024 Poster EPI JP03 neffy, Epinephrine Nasal Spray, Demonstrates a Positive Efficacy and Safety Profile for the Treatment of Allergic Reactions in Pediatric Patients at Risk of Anaphylaxis: Phase 3 Study Results 670.9 KB ACAAI 2023 Poster 7 Acute Allergic Rhinitis Increases Endogenous Epinephrine Resulting in Increased Heart Rate 678.5 KB Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Next page next › Last page last »
Blood Pressure and Pulse Rate Increases Without Concomitant Epinephrine Increases During Acute Allergic Reactions 683.1 KB
neffy, Epinephrine Nasal Spray, Development, from Pharmacokinetics and Pharmacodynamics to Real-World Data in Pediatric Food Allergy Patients 905.4 KB
Successful Administration of neffy, Epinephrine Nasal Spray, When Provided with a Two-Dose Carrying Case– A Human Factor Study 1.2 MB
ARS-2 (neffy), Low-Dose Intranasal Epinephrine, Improves Urticaria Scores in Patients with Frequent Urticaria Flares: Phase 2 Study Results 567.4 KB
A Survey of Allergists, Pediatricians, and Primary Care Physicians About the Utilization of Epinephrine 1.1 MB
Pediatric Doses of neffy (epinephrine nasal spray) Demonstrate Pharmacokinetic Profiles Equivalent to Epinephrine Injection Products 649 KB
neffy, Epinephrine Nasal Spray, Demonstrates a Positive Efficacy and Safety Profile for the Treatment of Allergic Reactions in Pediatric Patients at Risk of Anaphylaxis: Phase 3 Study Results 670.9 KB
